News

Learn how and why East Indian Sandalwood Oil (EISO) is making international headlines as a unique, non-substitutable botanical drug candidate.

Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil to Treat Pediatric Molluscum Contagiosum

Posted on

SAN ANTONIO–(BUSINESS WIRE)–Santalis Healthcare Corporation (formerly ViroXis Corporation),a wholly owned subsidiary of TFS Corporation, Ltd. (ASX:TFC), is pleased to announce that the first subject has been enrolled in a double-blind, placebo-controlled, randomized Phase 2 trial for the treatment of Molluscum contagiosum, testing a topical formulation of the company’s novel botanical drug candidate, East Indian Sandalwood Oil (EISO). Santalis Healthcare Corporation […]Read More Santalis Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil to Treat Pediatric Molluscum Contagiosum

Santalis Pharmaceuticals Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) in Oral Mucositis

Posted on

SAN ANTONIO(MEDIA)Santalis Pharmaceuticals, a clinical stage biopharmaceutical company developing innovative therapies for oncology supportive care and dermatology applications, is pleased to announce that the first subject has been enrolled in an open label Phase 2 trial for the prevention of oral mucositis, testing an oral rinse formulation of the company’s novel botanical drug candidate, East Indian Sandalwood Oil (EISO). Oral […]Read More Santalis Pharmaceuticals Announces First Subject Enrolled in Phase 2 Trial of East Indian Sandalwood Oil (EISO) in Oral Mucositis